NCT06625775 2026-03-18
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
BeOne Medicines
Boundless Bio, Inc.
Incyte Corporation
University of Chicago
Pfizer
Olema Pharmaceuticals, Inc.
OnKure, Inc.
Novartis
Pfizer
Biotheryx, Inc.